Adverse clinical events in patients treated with sirolimus-eluting stents: The impact of Type D personality

European Journal of Preventive Cardiology

Volumn 14, Issue 1, 2007, Pages 135-140

  Pedersen, Susanne S ^a,b   Denollet, Johan ^b   Ong, Andrew T l ^a   Sonnenschein, Karel ^a   Erdman, Ruud A M ^c   Serruys, Patrick W ^a   Domburg, Ron T Van ^a  

^a Department of Cardiology ^*  (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

Author keywords

mortality; myocardial infarction; percutaneous coronary intervention; sirolimus eluting stents; Type D personality

Indexed keywords

RAPAMYCIN;

ADULT; AGE; ARTICLE; BIOASSAY; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DISTRESS SYNDROME; DRUG ELUTING STENT; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PERSONALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SEX; SMOKING; TREATMENT OUTCOME; TYPE D PERSONALITY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERSONALITY; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 33847045147     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328045c282     Document Type: Article

References (30)

1. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT etal.; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New Engl J Med 2004; 350: 221–231.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M etal.; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Baloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–1780.
3. Colombo A, Drzewiecki J, Banning A, Grube E, Haputmann K, Silber S etal.; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788–794.
4. Holmes DR, Firth BG, Wood DL. Paradigm shifts in cardiovascular medicine. J Am Coll Cardiol 2004; 43: 507–512.
5. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583–591.
6. Lemos PA, Serruys PW, Van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared to conventional bare stent implantation in the ‘real world’. The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190–195.
7. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10: S1–S78.
8. Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease - recommendations for clinical practice. Eur J Cardiovasc Prev Rehabil 2004; 11: 75–79.
9. Blumenthal JA, Lett HS, Babyak MA, White W, Smith PK, Mark DB, et al. the NORG Investigators. Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet 2003; 362: 604–609.
10. Kop WJ, Appels AP, Mendes de Leon CF, De Swart HB, Bar FW. Vital exhaust on pred cts new card ac events after successful coronary angioplasty. Psychosom Med 1994; 56: 281–287.
11. Denollet J, Sys SU, Stroobant N, Rombouts H, Gillebert TC, Brutsaert DL. Personality as independent predictor of long-term mortality in patients with coronary heart disease. Lancet 1996; 347: 417–421.
12. Denollet J, Brutsaert DL. Personality, disease severity, and the risk of long-term cardiac events in patients with decreased ejection fraction after myocardial infarction. Circulation 1998; 97: 167–173.
13. Denollet J, Vaes J, Brutsaert DL. Inadequate response to treatment in coronary heart disease: adverse effects of Type D personality and younger age on 5-year prognosis and quality of life. Circulation 2000; 102: 630–635.
14. Pedersen SS, Denollet J. Type D personality, cardiac events, and impaired quality of life: a review. Eur J Cardiovasc Prev Rehabil 2003; 10: 241–248.
15. Schiffer AA, Pedersen SS, Widdershoven JW, Hendriks EH, Winter JB, Denollet J. Type D personality is independently associated with impaired health status and increased depressive symptoms in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2005; 12: 341–346.
16. Pedersen SS, Van Domburg RT, Theuns DAMJ, Jordaens L, Erdman RAM. Type D personality is associated with increased anxiety and depressive symptoms in patients with an implantable cardioverter defibrillator and their partners. Psychosom Med 2004; 66: 714–719.
17. Denollet J, Pedersen SS, Ong ATL, Erdman RAM, Serruys PW, Van Domburg RT. Social inhibition modulates the effect of negative emotions on cardiac prognosis following percutaneous coronary intervention in the drug-eluting stent era. Eur Heart J 2006; 27: 171–177.
18. Pedersen SS, Lemos PA, Van Vooren PR, Liu T, Daemen J, Erdman RAM, et al. Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation: a Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry sub-study. J Am Coll Cardiol 2004; 44: 997–1001.
19. Lemos P, Lee C, Degertekin M, Saia F, Tanabe K, Arampatzis CA, et al. Early outcome after sirolimus eluting stent implantation in patients with acute coronary syndromes: insights from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry. J Am Coll Cardiol 2003; 41: 2093–2099.
20. Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med 2005; 67: 89–97.
21. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al, American College of Cardiology, American Heart Association Task Force on Practice Guidelines. Committee to Revise the 1993 Guidelines for percutaneous transluminal coronary angioplasty. ACC∖AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines) -executive summary. A report of the American College of Cardiology∖American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37: 2215–2239.
22. Pedersen SS, Middel B. Increased vital exhaustion among Type D patients with ischaemic heart disease. J Psychosom Res 2001; 51: 443–449.
23. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143.
24. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104: 992–997.
25. Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, et al. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart 2003; 89: 1200–1204.
26. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary intervention. Eur Heart J 2004; 25: 1679–1687.
27. Denollet J, Conraads VM, Brutsaert DL, De Clerck LS, Stevens WJ, Vrints CJ. Cytokines and immune activation in systolic heart failure: the role of Type D personality. Brain Behav Immun 2003; 17: 304–309.
28. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001; 103: 2055–2059.
29. Oldridge N, Saner H, McGee HM; for the HeartQoL Study Investigators. The Euro Cardio-QoL Project. An international study to develop a core heart disease health-related quality of life questionnaire, the Heart QoL. Eur J Cardiovasc Prev Rehabil 2005; 11: 87–94.
30. Lemos PA, Serruys PW, Van Domburg RT. Sirolimus-eluting stents in the ‘real world’: The RESEARCH registry rationale and study design. In: Serruys PW, Lemos PA, editors. Sirolimus-eluting stents: From RESEARCH to clinical practice. London: Taylor & Francis; 2005. p. 17.